China Shineway Pharmaceutical Group Limited (CSWYY) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 6.47 means the share price is 6.47 times one year of earnings per share; the S&P 500 usually sits near 20-25. Beta 0.87: the stock has moved about 13% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerChina Shineway Pharmaceutical Group Limited (CSWYY) trades at $19.25. China Shineway Pharmaceutical Group Limited focuses on the research, development, manufacture, and trade of Chinese medicines. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for CSWYY: CSWYY does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CSWYY against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
CSWYY: 2/2 scored disciplines lean bullish. Dominant signal: Seth Klarman bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
China Shineway Pharmaceutical Group Limited (CSWYY) Healthcare & Pipeline Overview
China Shineway Pharmaceutical Group Limited, a subsidiary of Forway Investment Limited, develops, manufactures, and trades Chinese medicines, including TCM Formula Granules, targeting cardio-cerebrovascular, anti-viral, and orthopedic applications. With a 73.4% gross margin and a 5.54% dividend yield, the company operates primarily in the People's Republic of China and Hong Kong.
What Is the Investment Thesis for CSWYY?
A dividend yield of 5.54% offers an attractive income stream for investors. Growth catalysts include expanding its TCM Formula Granules offerings and penetrating new geographic markets within China. However, investors may want to evaluate risks associated with regulatory changes in the Chinese pharmaceutical industry and competition from both domestic and international players. The company's P/E ratio of 6.47 suggests a potentially undervalued stock, but further analysis is needed to assess long-term sustainability and growth prospects.
Based on FMP financials and quantitative analysis
CSWYY Key Highlights
Gross margin of 73.4% demonstrates strong pricing power and efficient cost management.
- Profit margin of 24.8% indicates healthy profitability in the Chinese pharmaceutical market.
- Dividend yield of 5.54% provides an attractive income stream for investors.
- P/E ratio of 6.47 suggests potential undervaluation compared to industry peers.
- Beta of 0.87 indicates lower volatility compared to the overall market.
Who Are CSWYY's Competitors?
CSWYY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ACOGF Alpha Cognition Inc. | $5.72 | 0.00% | $35.7M | — |
| BFFTF Biofrontera AG | $0.33 | -95.24% | $19.4M | — |
| CHBRF Chill Brands Group PLC | $0.05 | +48.84% | $24.5M | — |
| DMTTF Small Pharma Inc. | $0.11 | -9.69% | $37.5M | — |
| TAK Takeda Pharmaceutical Company Limited | $18.11 | -0.55% | $57.6B | 635-pillar |
| TEVA Teva Pharmaceutical Industries Limited | $36.65 | +0.84% | $42.7B | 605-pillar |
| HLN Haleon plc | $9.22 | -0.11% | $40.6B | 775-pillar |
| ZTS Zoetis Inc. | $72.89 | -0.57% | $30.6B | 855-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CSWYY's Key Strengths?
Established presence in the Chinese medicine market.
- Diverse product portfolio spanning multiple therapeutic areas.
- High gross margin and profit margin.
- Strong distribution network in China and Hong Kong.
What Are CSWYY's Weaknesses?
Reliance on the Chinese market.
- Exposure to regulatory changes in the pharmaceutical industry.
- Limited international presence.
- Potential competition from larger pharmaceutical companies.
What Could Drive CSWYY Stock Higher?
CSWYY catalyst: Increasing demand for TCM Formula Granules in China due to growing consumer preference for traditional medicine.
- Potential expansion into new geographic markets within China in Q4 2026.
- Strategic partnerships with other pharmaceutical companies to expand product offerings.
- Launch of new TCM products targeting specific health conditions in Q2 2027.
What Are the Key Risks for CSWYY?
Regulatory changes in the Chinese pharmaceutical industry could impact the company's operations and profitability.
- Increasing competition from domestic and international players in the Chinese medicine market.
- Fluctuations in the exchange rate between the U.S. dollar and the Chinese Yuan could affect the value of the ADR.
- Limited liquidity on the OTC market could make it difficult to buy or sell shares quickly.
What Are the Growth Opportunities for CSWYY?
- Expanding TCM Formula Granules: The market for TCM Formula Granules is growing rapidly due to increasing consumer preference for natural and traditional remedies. China Shineway can capitalize on this trend by expanding its range of TCM Formula Granules, targeting specific health conditions, and improving its distribution network. This market is estimated to reach $40 billion by 2028, offering significant growth potential.
- Geographic Expansion within China: While China Shineway has a presence in several regions of China, there is significant opportunity to expand into underserved markets. By establishing new distribution channels and marketing its products to a wider audience, the company can increase its sales volume and market share. This expansion could target Tier 3 and Tier 4 cities, where demand for affordable healthcare solutions is high.
- Strategic Partnerships: Collaborating with other pharmaceutical companies, research institutions, or healthcare providers can provide China Shineway with access to new technologies, products, and markets. Strategic partnerships can also help the company to reduce its R&D costs and accelerate its product development cycle. Potential partners include companies specializing in innovative drug delivery systems or personalized medicine.
- Product Innovation: Investing in research and development to create new and improved Chinese medicines is essential for long-term growth. China Shineway can focus on developing novel formulations, improving the efficacy of existing products, and addressing unmet medical needs. This includes exploring new applications for TCM in areas such as chronic disease management and preventative care.
- E-commerce and Online Sales: Leveraging e-commerce platforms to sell its products directly to consumers can significantly expand China Shineway's reach and reduce its reliance on traditional distribution channels. By establishing an online presence and offering convenient online ordering and delivery options, the company can tap into the growing online healthcare market. This includes partnering with established e-commerce giants in China.
What Threats Does CSWYY Face?
- Increasing competition from domestic and international players.
- Price pressures and reimbursement challenges.
- Patent expirations and generic competition.
- Changes in government regulations and policies.
What Are CSWYY's Competitive Advantages?
- Established brand reputation in the Chinese medicine market.
- Proprietary formulations and manufacturing processes.
- Strong distribution network in China and Hong Kong.
- Focus on both modern and traditional Chinese medicines.
What Does CSWYY Do?
China Shineway Pharmaceutical Group Limited, established in 2004 and headquartered in Shijiazhuang, China, operates as an investment holding company focused on the Chinese medicine market. The company researches, develops, manufactures, and trades a range of Chinese medicines, including modern formulations and traditional TCM Formula Granules. Its product portfolio spans several therapeutic areas, including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology. These medicines are produced in various forms such as soft capsules, granules, and injections. China Shineway distributes its products across the People's Republic of China and Hong Kong. The company's strategic focus on both modern and traditional Chinese medicine allows it to cater to a broad patient base. China Shineway Pharmaceutical Group Limited is a subsidiary of Forway Investment Limited, providing a stable ownership structure. In addition to its pharmaceutical activities, the company also engages in trading agricultural products, diversifying its business operations.
What Products and Services Does CSWYY Offer?
- Researches and develops Chinese medicines.
- Manufactures modern Chinese medicines in various forms (soft capsules, granules, injections).
- Produces TCM (Traditional Chinese Medicine) Formula Granules.
- Trades Chinese medicines in the People's Republic of China and Hong Kong.
- Focuses on therapeutic areas including cardio-cerebrovascular, anti-viral, orthopedics, pediatrics, gynecology, and gastroenterology.
- Trades in agricultural products.
How Does CSWYY Make Money?
- Develops and manufactures a portfolio of Chinese medicine products.
- Sells its products through distributors and directly to hospitals and pharmacies.
- Generates revenue from the sale of modern Chinese medicines and TCM Formula Granules.
- Trades agricultural products for additional revenue.
What Industry Does CSWYY Operate In?
China Shineway Pharmaceutical Group Limited operates within the growing Chinese pharmaceutical market, which is characterized by increasing demand for both modern and traditional Chinese medicines. The market is driven by an aging population, rising healthcare expenditure, and government support for the TCM industry. Competition is intense, with numerous domestic and international players vying for market share. China Shineway's focus on TCM Formula Granules positions it well to capitalize on the growing interest in traditional medicine. The company's ability to innovate and adapt to changing regulatory requirements will be crucial for sustained success.
Who Are CSWYY's Key Customers?
- Hospitals and clinics in China and Hong Kong.
- Pharmacies and drug stores.
- Patients seeking Chinese medicine treatments.
- Distributors of pharmaceutical products.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 73 days ago
- ● No analyst coverage
- ● Reported in CNY, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 43 |
| 2026-08-26 | 43 |
| 2026-08-29 | 43 |
| 2026-09-01 | 43 |
| 2026-09-04 | 43 |
| 2026-09-07 | 43 |
| 2026-09-10 | 43 |
What changed?
The score has stayed at 43.
Over the same 18 days the stock moved +0.0%.
Key Financial Metrics
Return on equity for China Shineway Pharmaceutical Group Limited stands at 12.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.8%, showing how much profit it generates from its asset base. CSWYY trades at a trailing price-to-earnings ratio of 6.47, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 22.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.71 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 19.7%, the inverse of the P/E and a quick read on earnings relative to price.
CSWYY Revenue & Earnings Trend
In Q2 FY2026, CSWYY generated $174.4M in top-line revenue, marking a sequential decrease of 19.7%. The company recorded net income of $69.3M, with diluted EPS of $36.68. Revenue has contracted over three consecutive quarters, which investors in this unknown Healthcare stock should monitor closely. Across the four most recent quarters, CSWYY averaged $31.96 in diluted EPS.
Company Profile
China Shineway Pharmaceutical Group Limited operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Shijiazhuang, CN. The company is led by CEO Zhenjiang Li. CSWYY has traded publicly since 2012.
Financial Health
China Shineway Pharmaceutical Group Limited's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 1.97 places it in the grey zone, a middle ground that warrants monitoring.
CSWYY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Established presence in the Chinese medicine market.
- Diverse product portfolio spanning multiple therapeutic areas.
- High gross margin and profit margin.
- Strong distribution network in China and Hong Kong.
Bear Case
- Reliance on the Chinese market.
- Exposure to regulatory changes in the pharmaceutical industry.
- Limited international presence.
- Potential competition from larger pharmaceutical companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $174M | $69M | $36.68 |
| Q4 FY2025 | $217M | $49M | $26.02 |
| Q2 FY2025 | $244M | $91M | $47.99 |
| Q4 FY2024 | $257M | $32M | $17.17 |
Q2 FY2026 · filed 30 Jun 2026 · Financial Modeling Prep
Based on FMP financials and quantitative analysis · Converted to USD from CNY at today's rate
CSWYY Latest News
-
Asian Dividend Stocks To Consider For Your Portfolio
Yahoo! Finance: CSWYY News · Dec 24, 2025
CSWYY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CSWYY.
Price Targets
Wall Street price target analysis for CSWYY.
CSWYY MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CSWYY; grades run from A+ (80-100) to F (below 30).
Leadership: Zhenjiang Li
CEO
Zhenjiang Li serves as the CEO of China Shineway Pharmaceutical Group Limited, overseeing the strategic direction and operational management of the company. His background includes extensive experience in the pharmaceutical industry, with a focus on Chinese medicine development and commercialization. He has a strong understanding of the regulatory landscape and market dynamics in China. His leadership is crucial for navigating the complexities of the Chinese pharmaceutical market and driving the company's growth.
Track Record: Under Zhenjiang Li's leadership, China Shineway has expanded its product portfolio and strengthened its market position in the Chinese medicine sector. Key achievements include increasing sales of TCM Formula Granules and improving the company's distribution network. He has also overseen investments in research and development to create new and improved Chinese medicines. He manages 3220 employees.
China Shineway Pharmaceutical Group Limited ADR Information Unsponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company trading on U.S. stock exchanges. CSWYY is an ADR representing shares of China Shineway Pharmaceutical Group Limited. This allows U.S. investors to invest in the company without directly dealing with foreign exchanges. Dividends are paid in U.S. dollars.
- Home Market Ticker: Hong Kong Stock Exchange (CSWY), China
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: CSWY
CSWYY OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that China Shineway Pharmaceutical Group Limited may have limited regulatory oversight and reporting requirements compared to companies listed on major exchanges like the NYSE or NASDAQ. Companies in this tier often have minimal financial disclosure and may not meet the listing standards of higher-tier exchanges. Investing in OTC Other stocks carries higher risks due to the lack of transparency and regulatory scrutiny.
- OTC Tier: OTC Other
- Limited regulatory oversight and financial disclosure.
- Potential for fraud or manipulation.
- Higher price volatility due to low trading volume.
- Difficulty in obtaining reliable information about the company.
- Risk of delisting or suspension of trading.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team and their track record.
- Check for any regulatory actions or legal disputes.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Established operating history in the Chinese medicine market.
- Presence of a recognized brand name.
- Positive financial performance (e.g., gross margin, profit margin).
- Listing on the Hong Kong Stock Exchange (CSWY).
- Subsidiary of Forway Investment Limited.
What Investors Ask About China Shineway Pharmaceutical Group Limited (CSWYY) — Healthcare
Is CSWYY a good stock?
Stock Expert AI does not rate CSWYY buy, sell or hold. China Shineway Pharmaceutical Group Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about CSWYY stock?
Analyst coverage for CSWYY is limited due to its OTC listing and smaller market capitalization. However, key valuation metrics such as the P/E ratio of 6.47 and a dividend yield of 5.54% suggest potential value.
What are the key factors to evaluate for CSWYY?
Evaluate CSWYY on fundamentals, analyst consensus, and risk factors. P/E: 6.47x vs the S&P 500's ~20-25x. A dividend yield of 5.54% offers an attractive income stream for investors. Not financial advice.
How frequently does CSWYY data refresh on this page?
CSWYY's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven CSWYY's recent stock price performance?
China Shineway Pharmaceutical Group Limited (CSWYY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established presence in the Chinese medicine market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CSWYY overvalued or undervalued right now?
China Shineway Pharmaceutical Group Limited (CSWYY) trades at 6.47x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of CSWYY?
Yes, most major brokerages offer fractional shares of China Shineway Pharmaceutical Group Limited (CSWYY) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CSWYY's earnings and financial reports?
China Shineway Pharmaceutical Group Limited (CSWYY) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for CSWYY earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited analyst coverage for CSWYY.
- OTC market carries higher risks compared to major exchanges.
- Financial data based on available information and may not be comprehensive.